Skip to main content
. 2021 Nov 9;36(3):561–567. doi: 10.1007/s10557-021-07291-y

Fig. 1.

Fig. 1

Effects of SGLT1/2 inhibition and GLP-1 receptor agonism on the incidence of myocardial infarction and stroke in patients with type 2 diabetes mellitus. BBB, blood brain barrier; Hct, hematocrit; MI, myocardial infarction; ROS, reactive oxygen species